Showing results 1 to 3 of 3
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus Journal:Molecular Cancer Therapeutics | 2015 | 65 | ||
2013 | 49 | |||
Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A) Proceeding/Conference:Journal of Clinical Oncology | 2010 | 52 |